Eli Lilly and Co.’s BLA for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy, has been assigned Priority Review by the FDA. Lilly anticipates agency action on this application in 2Q14. The priority designation aims to expedite the review of applications for drugs that, if approved, would represent a significant advance in treatment. This BLA for ramucirumab was based on data from REGARD, a global, randomized...